A Comprehensive Approach to Managing HER2-Positive Breast Cancer

A Comprehensive Approach to Managing HER2-Positive Breast Cancer
1 AMA PRA Category 1 Credit(s)
Launch Date:
October 03, 2017
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Oncologists, nurse practitioners, nurses, physician assistants, and other clinicians who specialize in oncology and management of patients with breast cancer

Relevant Terms:

Breast cancer, HER2+, immunohistochemistry, in-situ hybridization, targeted treatment, shared decision-making

Ruth M. O'Regan, MD

Ruth M. O'Regan, MD
Chief, Division of Hematology/Oncology and Palliative Care
Endowed Professor of Hematology/Oncology
Department of Medicine
University of Wisconsin School of Medicine and Public Health
Madison, WI

Ruth O’Regan, MD, is the division chief of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin. She previously was the Louisa and Rand Glenn Family Chair in Breast Cancer Research at Emory University in addition to being medical director at Glenn Family Breast Center of Emory University, and director of the Breast Cancer Translational Research Program at the Winship Cancer Institute.

Kate Carlson Wrammert, MSN, ANP-BC, WHNP-BC, AOCNP

Kate Carlson Wrammert, MSN, ANP-BC, WHNP-BC, AOCNP
Nurse Practitioner, McKelvey Lung Transplant Center
Emory University Hospital
Adjunct Faculty, Nell Hodgson Woodruff School of Nursing
Emory University
Atlanta, GA

Kate Carlson Wrammert, MSN, ANP-BC, WHNP-BC, AOCNP, is a board-certified nurse practitioner at the McKelvey Lung Transplant Center of Emory University Hospital in Atlanta, Georgia, where she is also adjunct faculty at the Nell Hodgson Woodruff School of Nursing. Ms Wrammert sits on the Jack & Jill Late Stage Cancer Foundation’s Medical Advisory Board, and has presented more than 25 invited lectures on subjects pertaining to breast cancer. Ms Wrammert previously spent 13 years as a Nurse Practitioner at the Winship Cancer Institute of Emory University.
1. Utilize the updated ASCO/CAP 2013 guidelines and the most recent NCCN guidelines for breast cancer to improve detection and classification of HER2 status
2. Apply current efficacy and safety data to select targeted treatments that improve outcomes for patients with HER2-positive breast cancer
3. Apply current guideline-recommended neoadjuvant and adjuvant treatments and appropriate treatment sequencing strategies for patients with HER2-positive breast cancer
4. Effectively engage patients with HER2-positive breast cancer in their healthcare by implementing effective shared decision-making strategies

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Ruth O'Regan, MD, has affiliations with Lilly (Consulting); and Oncothyreon (Contracted Research).
  • Kate Carlson Wrammert, MSN, ANP-BC, WHNP-BC, AOCNP, has no affiliations with commercial interest to disclose.
RMEI Medical Education, LLC
  • Elizabeth Paczolt, MD, has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine 
Planners and Managers
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose. 
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 1 hour
Media: Internet
There is no fee for this educational activity.
This activity is jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an independent educational grant from Genentech.  
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.